. 2019 Oct 26;14:120. doi: 10.1186/s13000-019-0901-6

Table 8.

Survival analysis. Mean survival of the patients within all types (n = 194) and ccRCC (n = 120); univariate and multivariate cancer-specific survival in the patients with ccRCC according to analyzed immunohistochemical markers and clinic-pathologic parameters

Prognostic factors	Cancer-specific survival (months)
					Univariate		Multivariate
	All types mean (95% CI)	p-value	ccRCC mean (95% CI)	p-value	Hazard ratio (95% CI)	p-value	Hazard ratio (95%CI)	p-value
PRMT1
positive	78 (73–84)	0.009*	74 (66–82)	0.029*	0.504 (0.269–0.947) Ref.	0.033*	0.622 (0.326–1.188)	0.150
negative	56 (48–63)	0.009*	51 (42–61)	0.029*	0.504 (0.269–0.947) Ref.	0.033*	0.622 (0.326–1.188)	0.150
ZEB1
positive	83 (76–91)	0.011*	80 (70–90)	0.009*	0.344 (0.140–0.801)	0.014*	0.367 (0.152–0.889)	0.026
negative	68 (61–74)	0.011*	52 (45–60)	0.009*	0.344 (0.140–0.801)	0.014*	0.367 (0.152–0.889)	0.026
RUNX1
positive	75 (68–82)	0.937	67 (60–74)	0.506	0.872 (0.463–1.644)	0.673	N/A
negative	69 (61–78)	0.937	57 (48–66)	0.506	0.872 (0.463–1.644)	0.673	N/A
TWIST1
positive	73 (68–78)	0.886	67 (60–74)	0.878	1.168 (0.159–8.553)	0.879	N/A
negative	54 (34–75)	0.886	54 (34–75)	0.878	1.168 (0.159–8.553)	0.879	N/A
Grade	N/A
Low			67 (62–72)	<0.001*	5.802 (3.000–11.222)	<0.001*	6.284 (3.175–12.438)	<0.001*
High			25 (18–32)	<0.001*	5.802 (3.000–11.222)	<0.001*	6.284 (3.175–12.438)	<0.001*
Stage	N/A
Low			70 (63–76)	<0.001*	1.062 (0.849–1.330)	0.597	1.187 (0.912–1.547)	0.203
High			48 (36–60)
PN			63 (51–74)
Gender
Male	75 (66–83)	0.686	58 (51–65)	0.736	1.123 (0.569–2.218)	0.737	N/A
Female	72 (66–78)	0.686	70 (58–81)	0.736	1.123 (0.569–2.218)	0.737	N/A

Abbreviations: PRMT1 protein arginine methyltransferase 1, ZEB1 Zinc Finger E-Box Binding Homeobox 1, RUNX1 Runt-related transcription factor 1, TWIST1 Twist Family BHLH Transcription Factor 1, CI confidence interval, PN partial nephrectomy, ref. referent value. *Statistically significant p-value